 There are currently no licensed drugs in the EU to treat thrombocytopenia in MDS patients classified as IPSS lowint-1. Prior studies with romiplostim a TPO receptor agonist in MDS found that baseline concentration of TPO as well as transfusion history were predictive of subsequent response in a retrospective model. 